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Monoallelically Expressed Gene Related to p53
at 1p36, a Region Frequently Deleted
in Neuroblastoma and Other Human Cancers
Mourad Kaghad,* Helene Bonnet,* Annie Yang,² p53 acts as a tumor suppressor; its loss of function
Laurent Creancier,* Jean-Christophe Biscan,* appears to confer selective advantages on cells through
Alexandre Valent,³ Adrian Minty,* Pascale Chalon,* deregulated growth and resistance to cell death (Grae-
Jean-Michel Lelias,* Xavier Dumont,* ber et al., 1996; Kinzler and Vogelstein, 1996).
Pascual Ferrara,* Frank McKeon,² Despite the widespread presence of p53 mutations
and Daniel Caput*§ in human malignancies, many tumors develop in the
*Sanofi Recherche absence of p53 abnormalities or obvious tumor anti-
Innopole B.P. 137 gens, most likely due to a loss of other tumor suppressor
31676 Labege CEDEX genes (Weinberg, 1993). Many of these tumor suppres-
France sor genes, including Rb in retinoblastoma, NF1 in neu-
²Department of Cell Biology rofibramatosis, and DCC and APC in colon carcinomas,
Harvard Medical School were initially identified through cytogenetic evidence of
Boston, Massachusetts 02115 loss of heterozygosity (LOH) (Benedict et al., 1983;
³Lab. de Cytogenetique et Genetique Cavenee et al., 1983; Ballester et al., 1990; Buchberg et
Oncologiques al., 1990; Fearon et al., 1987).
URA 1967 CNRS Similarly, extensive investigations of neuroectodermal
Institut Gustave Roussy tumors, including neuroblastoma, melanoma, and multi-
Villejuif ple endocrine neoplasm, have suggested the presence
France of multiple tumor suppressors at the subtelomeric re-
gion of chromosome 1 (Brodeur et al., 1977; Balaban et
al., 1986; Ross et al., 1995; Sozzi et al., 1988; Dracopoli
Summary et al., 1989). Neuroblastomas with 1p LOH can be subdi-
vided into two classes as having either small deletions
We describe a gene encoding p73, a protein that (5 to 10 Mb) at 1p36.2-3 or a clinically more aggressive
shares considerable homology with the tumor sup- form characterized by N-myc amplification and larger
pressor p53. p73 maps to 1p36, a region frequently deletions of chromosome 1 including subbands p36 and
deleted in neuroblastoma and other tumors and p35 (Brodeur et al., 1984; Takeda et al., 1994; Caron et
thought to contain multiple tumor suppressor genes. al., 1995). Notably, the chromosome that sustains the
Our analysis of neuroblastoma cell lines with 1p and discrete 1p36 deletion of the firstclass of neuroblastoma
p73 loss of heterozygosity failed to detect coding se-
is almost exclusively of maternal origin, indicating that
quence mutations in remaining p73 alleles. However,
the putative tumor suppressor in this region is imprintedthe demonstration that p73 is monoallelically ex-
(Barlow, 1995; Caron et al., 1995). In contrast, N-myc-pressed supports the notion that it is a candidate gene
amplified neuroblastomas show a LOH at 1p35-1pterin neuroblastoma. p73 also has the potential to acti-
from either chromosome (Caron et al.,1995; Cheng etal.,vate p53 target genes and to interact with p53. We
1995). These observations suggest that neuroblastomapropose that the disregulation of p73 contributes to
develops through different mechanisms of inactivatingtumorigenesis and that p53-related proteins operate
alleles of putative tumor suppressors at 1p36 and thatin a network of developmental and cell cycle controls.
additional genes, at 1p35 and at other loci, influence
tumorigenesis. The etiology of neuroblastoma is compli-Introduction
cated by an additional class of neuroblastoma, referred
to as 4S, that initially appears as a widely disseminated,Spontaneous lesions in the gene encoding the tumor
aggressive disease (Ambros et al., 1995). Remarkably,suppressor p53 have been implicated in the progression
a majority of the 4S neuroblastomas suddenly and spon-of a wide range of human tumors (Nigro et al., 1989;
taneously regress in the absence of treatment. Under-Hollstein et al., 1991; Levine et al., 1995). The prevalence
standing these complex pathways of neuroblastoma in-of tumors in individuals or mice bearing constitutional
duction and progression will require the identificationp53 mutations suggests that loss of p53 activity also
of the provisional tumor suppressors located on thecontributes to the generation of tumors (Li and Fraumeni,
1969; Malkin et al., 1990; Donehower et al., 1992; Jacks short arm of chromosome 1.
et al., 1994). Wild-type p53 can also be neutralized We have identified a novel gene encoding a protein,
through direct interaction with either cellular proteins or termed p73, with remarkable sequence similarity to the
viral tumor antigens (Lane and Crawford, 1979; Linzer DNA-binding, transactivation, and oligomerization do-
and Levine, 1979; Werness et al., 1990). p53 appears mains of p53. We show that p73 has oligomerization
to induce cell cycle arrest or apoptosis in response to and transactivation properties similar to p53 and that
cellular stresses such as DNA damage and hypoxia the p73 gene maps to the 1p36.33 region frequently
(Kastan et al., 1992; Livingstone et al., 1992; Lowe et deleted in neuroblastoma and other tumors. In addition,
al., 1993; Hartwell and Kastan, 1994). By this means, we provide evidence to support the notion that alter-
ations in p73 gene expression may be one factor in the
development of neuroblastoma and other tumors.§To whom correspondence should be addressed.
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Figure 1. Homology between p73 and p53
Primary amino acid sequences of human p73a and b were deduced from cDNAs from normal human tissues.
(A) Comparative alignments of coding sequence and gene structure of human p73a and p53. Identities are enclosed in shaded boxes, with
p53 residues frequently mutated in tumors presented in bold. The identity and position of introns within p73 and p53 genes are denoted
above and below the respective sequences.
(B) C-terminal sequence of human p73b, a splicing variant lacking exon 13, is aligned with its site of divergence from p73a.
(C) Homology between the C-terminal sequence of p73a and that of a p53-like protein from squid.
(D) Summary of yeast two-hybrid interaction assays between p53, p73a, and p73b, presented as ordinate values relative to B-galactosidase
activity of p53±p53 interactions.
Results Prives, 1996) are conserved and occupy identical posi-
tions in p73 (Figure 1a). No significant homology was
Homology between p73 and the p53 detected between the C-terminal domain (364±393) of
Tumor Suppressor mammalian p53 and p73. However, the C-terminal do-
A cDNA encoding p73 was fortuitously discovered in a main of human p73a shows homology with recently dis-
hybridization screen of a COS cell cDNA library using covered invertebrate p53 homologs (Figure 1c), sug-
degenerate oligonucleotides corresponding to IRS-1- gesting the possibility that p53 may have evolved from
binding domains. The coding sequence of p73 was a more primitive, p73-like gene. In support of this con-
found to lack any homology to IRS-1 binding domains. cept, the intron±exon organization of the p73 gene was
Subsequently, libraries of normal human colon tissue found to be similar to that of the p53 gene (Figure 1a).
cDNAs were screened by hybridization to yield cDNAs p73b is encoded by transcripts lacking the 96 nucleo-
encoding p73a and p73b, which are splicing variants of tides corresponding to exon 13. This deletion interrupts
p73 differing at their C termini (Figures 1a and 1b). The the open reading frame, yielding a polypeptide of 499
homology between p73 and p53 is extensive within the amino acids (Figure 1b). Both p73a and b transcripts
most conserved p53 domains (Zambetti and Levine, were detected by PCR in all human tissues tested, in-
1993; Ko and Prives, 1996) involved with transactivation
cluding brain, kidney, placenta, colon, heart, liver, spleen,
(29% identity with p53 amino acids 1±45), DNA binding
and skeletal muscle (data not shown), indicating a wide-(63% identity with p53 amino acids 113±290), and p53
spread, albeit low level, expression of these proteins.oligomerization (38% identity in p53 sequence from
Considering the extensive homology between p53319±363) (Figures 1a and 1c). While the homology be-
and p73, including that in the oligomerization domaintween the N terminus of p73 and that required for tran-
of p53, we assessed whether these proteins would inter-scriptional activation by p53 is not strong, a sequence
act in the context of the yeast two-hybrid system (Gyurissimilar to the MDM2-binding domain of p53 (TFSDLW;
et al., 1993). Using this assay, we detected strong homo-Lin et al., 1994a) is present in p73 as TFEDLW. Signifi-
typic interactions between p53 molecules, indicative ofcantly, residues corresponding to those of p53 fre-
their known ability to form oligomers (Ko and Prives,quently mutated in tumors (R175, G245, R248, R249,
1996). In contrast, p73a showed a very low tendencyR273, and R282) and shown to be requiredfor sequence-
specific DNA recognition (Lin et al., 1994b; Ko and to form homotypic interactions in this assay. However,
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arm of chromosome 1 appear frequently in neuroblas-
toma (Takeda et al., 1994; Caron et al., 1995; Cheng et
al., 1995), we performed p73 FISH analysis on various
human cell lines established from neuroblastoma tu-
mors. The SK-N-AS has the smallest 1p deletion of de-
fined neuroblastoma cell lines covering approximately
8 Mb, limited distally by D1Z2 (1p36.33) and proximally
by TNFR2 (1p36.2) (Figure 2b; White et al., 1995; Cheng
et al., 1996). Probing of SK-N-AS with the p73 gene
yielded signal from only one of the two chromosome 1
homologs, demonstrating a p73 LOH in this neuro-
blastoma cell line (Figure 2a). Subsequent, more detailed
mapping has indicated that the p73 gene is very close
to the D1Z2 marker at 1p36.33, thereby placing p73 at
the distal border of the consensus region of deletion in
neuroblastoma (Figure 2b).
A similar FISH analysis of neuroblastoma cell lines
showing N-Myc amplification and a larger 1p deletion,
including IMR-32 and CHP-212, confirmed the LOH of
the p73 gene in these cells (Table 1). Interestingly, both
the SK-N-SH and the SK-N-MC neuroblastoma cell lines
show neither 1p (Davidoff et al., 1992; Cheng et al., 1996)
nor p73 LOH (Table 1), indicating that either other lesions
are responsible for these tumors or that p73 is inacti-
vated by mechanisms besides deletions in these cell
lines.
Figure 2. Mapping of p73 Gene to 1p36 and LOH in Neuroblastoma
Cell Line
(A) (Left panel) Fluorescence in situ hybridization (FISH) of a cosmid p73 Expression in Neuroblastoma Cell Lines
probe containing the p73 gene on a normal human chromosome To examine p73 and p53 expression in neuroblastomaspread. Chromosomes (in red) are counterstained with propidium
cell lines, we developed sensitive RT-PCR reactions toiodide, and p73 gene signals appear as green at the telomere of
yield amplicons corresponding to the entire coding se-1p. (Right panel) FISH analysis on chromosome spreads of the SK-
N-AS neuroblastoma cell line reveals two chromosome 1 homologs quences of p73 and p53 transcripts. RT-PCR products
using the centromeric D1Z5 probe (red) but only one chromosome of p73 transcripts were first obtained from IMR-32, SK-
1 with a p73 signal (green). Chromosomes are counterstained with N-MC, SK-N-SH neuroblastoma cell lines, as well as the
DAPI (blue). HT-29 colon carcinoma cell line, but not from the SK-
(B) Summary of cytogenetic data for the localization of the neuro-
N-AS cell line (Figure 3a). To gain quantitative informa-blastoma suppressor locus at 1p36, based on overlapping regions
tion on levels of p73 transcript expression, Northernof deletion in neuroblastoma cell lines and detailed mapping of the
1p deletion in the SK-N-AS cell line (Cheng et al., 1996). Approximate analysis was performed on these same cell lines. Two
positions of genes (in red) and polymorphic markers (in black) are p73 transcripts of 4.4 and 2.9 kb, corresponding to poly-
noted. adenylation variants as determined by direct sequenc-
ing, were detected in HT-29, IMR-32, and SK-N-SH
mRNA, while p73 transcripts were either not detected
p73b displayed strong homotypic interactions, equiva- in RNA from SK-N-AS cells or present at exceeding
lent to that of p53. The potential for heterotypic interac- low levels in SK-N-MC cells (Figure 3b, upper panel).
tions was also assayed by the two-hybrid system. Inter- Corresponding Northern analysis of p53 transcripts in
estingly, p53 and p73b displayed significant mutual these cell lines revealed a common 2.5 kb transcript
interactions in either bait or prey configuration, while except for SK-N-MC, which displays a previously char-
p53 showed negligible interactions with p73a. Weak but acterized truncation (Figure 3b, lower panel; Davidoff et
detectable interactions between p73a and p73b were al., 1992). Western blots to detect the p73a protein were
also evident in this assay. The physiological significance performed using a polyclonal antibody directed against
of the apparent oligomerization and restricted hetero- the C terminus of p73a. Reflecting the Northern data for
typic interactions amongst p73a, p73b, and p53 deter- p73 transcripts in these cell lines, extracts from HT-29,
mined in these assays remains to be established. IMR-32, and SK-N-SH cells showed easily detectable
levels of the p73a protein. However, SK-N-MC and SK-
N-AS extracts contained significantly reduced levels ofp73 Gene Localized to Neuroblastoma
Suppressor Locus at 1p36 p73a, showing only a faint band that migrates somewhat
faster than the main product seen for HT-29, IMR-32,To test the possibility that the p73 gene was located at
sites of suspected tumor suppressor genes, we mapped and SK-N-SH (Figure 3c). To characterize further the
expression pattern of p73, we performed immunolo-the p73 gene using fluorescence in situ hybridization
(FISH) on normal human chromosome spreads. The p73 calization of the endogenous p73a in an array of cell
lines, all of which revealed a pattern of small, punctatecosmid probe hybridized to the subtelomeric p36 region
of chromosome 1 (Figure 2a). As deletions in the short dots in the nucleus of some cells in an asynchronous
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Table 1. Analysis of p73 in Neuroblastoma and Other Tumor Cell Lines
Gene D1Z5 Expressed Transcript p53
Cell Lines 1pD1 Copy #2 Copy #3 Allele(s)4 Allele5 Sequence6 Protein7 Transcript8
Neuroblastomas
(N-Myc amplified)
IMR-32 Yes 1 3 A/T; (2) A/T wt 1 wt
CHP-212 Yes 1 3 A/T; (2) A/T* wt 2 wt
SMS-BC Yes NT NT G/C; (2) G/C* wt 2 mut [135C→F]
SK-N-BE(2) Yes NT NT G/C; (2) G/C wt 2 mut [135C→F]
SMS-KAN Yes NT NT G/C; (2) G/C* wt 2 wt
(N-Myc single copy)
SK-N-AS Yes 1 2 G/C; (2) G/C* wt 2 wt
SK-N-MC No 2 2 G/C;G/C G/C wt/mut [472A→T] 2 Dexons2±4
SK-N-SH No 2 2 G/C;A/T A/T wt/Dexon2d 1 wt
Others
NCI-1011 NR NT NT G/C; (?) G/C wt 1 mut [176C→F]
HT-29 NR NT NT G/C; (?) G/C wt 1 mut [273R→H]
A-172 NR NT NT G/C; (?) G/C wt 1 wt
U-373 NR NT NT G/C; (?) G/C wt 1 mut [273R→H]
K-562 NR NT NT G/C; (?) G/C wt 1 frame shift
IM-9 NR NT NT G/C; (?) G/C wt 1 wt
SAOS-2 NR 3 5 G/C;G/C G/C wt 2 (-)
MCF-7 NR 3 2 G/C;G/C G/C wt 1 wt
U-937 NR 3 4 G/C;G/C (-) N/A 2 (-)
HL-60 NR 2 2 G/C;G/C (-) N/A 2 (-)
SW-480 NR NT NT G/C; (?) G/C wt 1 mut [273R→H]
mut [309P→S]
11pD, deletion in short arm of chromosome 1, as cited in text. NR, none reported.
2Determined by fluorescence in situ hybridization (FISH) with a p73 genomic probe on chromosome spreads, performed as described in
Experimental Procedures. NT, not tested.
3Determined by FISH analysis with the chromosome 1 centromeric probe, D1Z5 (Oncor). NT, not tested.
4Refers to the polymorphism of G/C and A/T alleles, as determined by PCR on genomic DNA and PCR-RL (see Figure 4 and Experimental
Procedures) of products. Minus sign (2) indicates p73 loss of heterozygosity, assumed on the basis of known 1p36 deletions. For cell lines
in which chromosome 1p deletions have not been reported (NR), the A/T allele was never detected, though the presence of other non-G/C
or A/T alleles cannot be formally excluded (denoted by question mark).
5Determined by RT-PCR on mRNA and subsequent sequencing of products. Asterisks indicate a second, 30-cycle round of PCR was required
to generate products for sequencing. (-) indicate a lack of detectable product, despite two rounds of RT-PCR.
6Determined by sequence analysis of open reading frame in expressed transcripts. wt, wild type compared with normal human tissue (not
shown); N/A, not available due to lack of mRNA expression, as determined by RT-PCR. d indicates 10% of transcripts sequenced contained
a deletion in exon 2.
7Detectable by Western blotting of whole cell lysates, as described in Figure 3 and Experimental Procedures.
8Same as 6, performed on p53 mRNA.
population (Figure 3d). A similar distribution of dots was from control, nonneuroblastoma lines, were sequenced
in their entirety and found to be identical to p73 se-revealed upon transfecting mammalian cells with a myc
epitope-tagged p73a expression vector, indicating that quences derived from normal human tissue (Table 1).
Western blot analysis of the four neuroblastoma linesp73 autonomously targets to these intranuclear foci (Fig-
ure 3d). that showed extremely low levels of p73 transcript by
RT-PCR revealed a corresponding lack of p73a protein
(Table 1). In addition, two neuroblastoma lines, SK-N-Lack of Coding Region Mutations in p73 Gene
As most neuroblastoma cell lines examined displayed BE(2) and SK-N-MC, showed detectable levels of p73
transcripts by one round of PCR but no p73a protein.a LOH of the p73 gene, we asked whether the remaining
allele sustained genetic changes that might affect p73 These results, together with the absence of mutations
in the remaining allele of p73 LOH neuroblastoma cellfunction. We used the p73 RT-PCR reaction to amplify
the coding region of p73 from mRNA of an extended lines, suggest that epigenetic mechanisms such as im-
printing and translational suppression act to limit p73group of neuroblastoma cell lines. As with SK-N-AS, the
neuroblastoma lines SMS-BC, CHP-212, and SMS-KAN expression in neuroblastoma cells.
showed no RT-PCR product corresponding to p73 after
30 cycles, suggesting very low expression levels. How- Monoallelic Expression of the p73 Gene
Through our analysis of p73 transcripts in neuro-ever, reamplification for an additional 30 cycles yielded
sufficient product for sequencing p73 transcripts from blastoma cell lines and tumors, we discovered an allelic
polymorphism consisting of a double nucleotide substi-these lines. These PCR products, including six from
neuroblastoma cell lines displaying a 1p36 LOH (IMR-32, tution (G→A) and (C→T) at positions 4 and 14 of exon
2, just upstream of the initial AUG of p73 (Figure 4a).CHP-212, SMS-BC, SMS-KAN, SK-N-BE(2), and SK-N-
AS), two from neuroblastoma cell lines that showed no We denote these two naturally occurring p73 alleles G/C
and A/T. The G/C, A/T polymorphism occurs in a region1p deletion (SK-N-SH and SK-N-MC), as well as those
p73, a Gene at Chromosome 1p36, Is Related to p53
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over the other. We addressed this issue by performing
the assay on G/C and A/T transcripts mixed at known
ratios and showed that this assay was not obviously
biased for one allele. Moreover, this analysis showed
that we could detect both transcripts even when they
are present in ratios of 20:1 (Figure 4d). To examine
further the possibility of monoallelic expression of p73,
we performed PCR-RL on transcripts of peripheral blood
cells from five healthy donors determined to be G/C;A/T
heterozygotes. All five PCR-RL assays revealed a p73
pattern corresponding to either, but not both, the A/T
or the G/C allele, supporting the notion of monoallelic
expression of p73, at least within the 20-fold sensitivity
of this assay (Figures 4c and 4d). Thus, monoallelic ex-
pression of p73 may have particular significance for
neuroblastoma and other tumors that display 1p36 LOH,
as deletion of the active allele may result in a nearly
complete loss of p73 activity. Finally, p73a protein ex-
pression was easily detected in a majority of nonneuro-
blastoma cell lines. In contrast, only two of eight neuro-
blastoma cell lines yielded p73a signal on Western
Figure 3. Analysis of p73 Expression in Cell Lines blots, and these exclusively express the A/T transcript
(Table 1).(A) RT-PCR products corresponding to the coding regions of p53
and p73a from various cell lines used for sequence analysis (see
text).
(B) Northern blot analysis of p73 and p53 transcripts in selected cell p21waf Induction and Growth Suppression by p73
lines. The 4.4 and 2.9 kb p73 transcripts result from the use of The SK-N-AS cell line expresses no detectable p73 pro-
distinct polyadenylation sites. All cell lines show a similar 2.5 kb
tein and negligible levels of p73 transcript and thereforep53 transcript except SK-N-MC, which contains a previously char-
represented an ideal model for testing the effect of rein-acterized deletion (Davidoff et al., 1992).
troducing p73 (Baker et al., 1990). SK-N-AS cells were(C) Western blot analysis of total cell lysates cell lines using poly-
clonal antibody directed to C terminus of p73a (top) and monoclonal transfected with a plasmid expressing both the se-
antibody to p53 (bottom). lectable marker for neomycin resistance (Neor) and ei-
(D) Immunolocalization of endogenous and transfected p73a in cell ther wild-type p73a or p73a(R292H), a mutant version
lines. (Top left panel) Immunolocalization of endogenous p73a in
homologous with p53(R273H) that is defective for DNAU251 human glioblastoma cell line using anti-p73a antibodies, re-
binding and transcriptional activation (Lin et al., 1994a;vealing numerous discrete foci with the nucleus of some, but not
Ko and Prives, 1996). Wild-type p53 or p53(V143A)all cells in field. (Top right panel) Hoechst dye staining of field corre-
sponding to left panel, revealing nuclei of cells. (Bottom left panel) (Baker et al., 1990) were transfectedseparately and used
Immunolocalization of myc epitope±tagged p73a in baby hamster for comparison with p73 samples. Cells were grown in
kidney cells transfected with a p73a expression vector. (Bottom the presence of G418, a neomycin analog, and one set
right panel) Hoechst dye stained nuclei corresponding to field pre-
of plates harvested after 48 hrs for Western blottingsented at left.
analysis. Lysates from the transfected cells were probed
with antibodies to detect the expression of p73 or p53
as well as p21waf, a known p53 target gene (El-Deiry etof the transcript that could theoretically form a stem-
loop structure, possibly an indication of regulatory func- al., 1993). Significantly, cells expressing wild-type p73
showed elevated levels of p21 protein, comparable totion. Interestingly, sequencing of p73 transcripts from
a wide variety of nonneuroblastoma cell lines, listed in those seen in wild-type p53 transfectants, whereas mu-
tant p73- and mutant p53-expressing cells both failedTable 1, revealed only the G/C allele, while three of eight
neuroblastoma lines possessed an A/T allele. We used to show a similar p21waf induction (Figure 5a).
We further tested the effect of exogenously expressedPCR-restriction length analysis (PCR-RL) to screen rap-
idly for allele types at both the DNA and transcript levels, p73 on SK-N-AS cells using a standard colony assay
(Baker et al., 1990). Identical sets of plates to thosetaking advantage of the additional Sty1 site resulting
from the double substitution (G→A and C→T) in exon 2 above were maintained under G418 selection for 3
weeks and assayed for colony production. No colonies(Figures 4b and 4c). Notably, the single remaining allele
of both IMR-32 and CHP-212 bears the A/T polymor- were obtained from cells expressing wild-type p73 or
p53 (Figure 5b), while the DNA-binding domain mutantsphism (Table 1). We were especially intrigued by the
analysis of the SK-N-SH cell line, which shows no p73 of each yielded high numbers of colonies. Although the
physiological significance of colony assays in generalLOH and has both G/C and A/T alleles at the genomic
level. At the transcript level, however, using RT-PCR- is unclear, the obvious distinction between the wild-
type versions of p73 and p53 and their counterpart mu-RL, we could only detect expression of the A/T allele
(Figure 4c). This result suggested that, at least in SK- tants that fail to bind DNA suggests that the observed
growth suppression and endogenous p21 activation inN-SH cells, p73 protein is a consequence of monoallelic
expression. Another possibility that might explain this SK-N-AS cells are a function of the transcription activity
of p73 and p53.result is that our RT-PCR-RL assay may favor one allele
Cell
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Figure 4. Monoalleleic Expression of p73
Gene
(A) Sequence of exon 2 alleleic variants of
p73a transcripts deduced from RT-PCR
product sequencing. The two alleles, which
represent dinucleotide substitutions at posi-
tion 4 and 14 of exon 2, are G4/C14 and A4/
T14 and appear at a region of the 59-untrans-
lated sequence that might form a stem-loop
structure.
(B) Genotypic analysis of p73 G/C and A/T
alleles in ten normal blood donors using PCR-
RL. Genomic PCR products that include exon
2 yield a 482 bp fragment. Sty1 digestion of
PCR products yields two smaller size frag-
ments from AT allele-derived amplicons of
376 bp and 106 bp, respectively, whereas the
GC allele-derived amplicons remain uncut
(lanes 1, 2, 3, 4, 6, 7, and 10). The lanes 5, 8,
and 9 show heterozygotes GC/AT donors.
(C) Analysis of G/C A/T p73 allele expression using Sty1 and Nar1 digestions of transcript RT-PCR products from cell lines and five p73
heterozygote GC/AT individuals (1±5). As with the genomic analysis, the double digestion of RT-PCR products yields specific fragments
identitying each type of allele transcript-derived amplicons (284 bp for GC and 234 bp and 50 bp for AT transcripts). IMR-32, SK-N-SH, as
well as blood cells of individuals 1, 3, 4, and 5 predominantly express the A/T allele at the transcript level, while HT-29 and individual 2 express
the G/C allele in transcripts.
(D) A/T G/C titration assay to determine sensitivity and bias potential of RT-PCR-RL analysis for alleleic expression. G/C and A/T transcripts
from total mRNA of HT-29 and IMR-32 respectively were quantified by Northern blots and mixed at the ratios indicated and analyzed by the
RT-PCR-RL assay described for (C). A/T and G/C alleles can be detected even when mixed with a 20-fold excess of the other allele.
p73 Is Not Activated by Actinomycin D Discussion
or UV Irradiation
The identification of a novel gene located at chromo-In light of the structural similarities between p73 and
some 1p36.2-3 that encodes proteins with significantp53, we asked whether p73, like p53, is induced by
homology to p53 may have implications for our under-agents that activate the DNA damage checkpoint (Ko
standing of the etiology of neuroblastoma and otherand Prives, 1996). To do this, p53 and p73 protein levels
tumors as well as for p53 evolution and function. Thewere assayed in IMR-32 cells following exposure to ei-
remarkable homology between the core domain of p73ther actinomycin D or ultraviolet radiation (Kessis et
and the DNA-binding domain of p53, together with p73'sal., 1993; Caelles et al., 1994). Actinomycin D at low
ability to induce the p21waf protein, suggest that p73concentrations (1 nM) activates theDNA damage check-
acts, in part, as a transcription factor. While it is notpoint through producing DNA strand breaks, while at
obvious that p73 and p53 share common functions, thehigher concentrations (1 to 2 mM) inhibits transcription
presence of distal 1p alterations ina wide array of tumors(Kessis et al., 1993; Caelles et al., 1994). After 24 hrs of
in addition to neuroblastoma, including melanoma (Dra-treatment with 1 nM actinomycin D, p53 and p21waf levels
copoli et al., 1989), hepatocellular carcinoma (Yeh et al.,in the cell are markedly elevated, while p73a levels ap-
1994), and ductile breast carcinoma (Genuardi et al.,pear unaffected (Figure 6a). At micromolar concentra-
1989), supports the notion that p73 operates in path-tions of actinomycin D that inhibit transcription, p53
ways that coordinate cell growth, death, and differenti-
levels continue to rise above those of untreated cells,
ation.
presumably due to a stabilization of the p53 protein. In
contrast, p21 and p73a protein levels were not enhanced Neuroblastoma: LOH and Monoallelelic
by actinomycin D over those of untreated cells (Figure Expression of p73 Gene
6a). Similar results were obtained with other cell lines. Neuroblastoma is thought to arise from primitive neu-
To assess further the effect of DNA damage on p73a roectodermal stem cells that fail, at various stages, to
levels, IMR-32 cells were exposed to ultraviolet (254 nm) differentiate into sympathetic neurons, Schwann cells,
radiation and subsequently probed with antibodies to or melanocytes (Knudson and Meadows, 1980; Ross et
p73a, p53, and p21. Although p53 protein was markedly al., 1995). Associated cytogenetic characteristics in-
increased in cells at 15 hrs after irradiation, p73a levels clude discrete and gross deletions of the short arm of
fail to show a similar increase after such treatments chromosome 1, the amplification of N-Myc, and distur-
(Figure 6b). A similar failure to induce p73a was ob- bances in cell ploidy (Takeda et al., 1994; Ambros et al.,
served in cells exposed to gamma radiation or genotoxic 1995; Caron et al., 1995; Cheng et al., 1995). Genetic
agents such as doxorubicin (data not shown). Thus, analyses of neuroblastoma tumors harboring discrete
despite the structural similarities between p73 and p53 1p36.2-3 LOH have shown this deletion to be sustained
and their common ability to induce p21waf, these proteins predominantly by the maternally derived chromosome,
do not respond in a similar manner to DNA damaging thereby implicating one or more imprinted tumor sup-
pressor genes in this region (Versteeg et al., 1995). Inevents.
p73, a Gene at Chromosome 1p36, Is Related to p53
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Figure 6. p73 Induces p21 but Is Not Responsive to DNA Damage
(A) Immunoblots of lysates prepared from IMR-32 cells treated with
either 1 nM actinomycin D for 24 hrs or 1 mM actinomycin D for 2
hrs were probed with antibodies to p73a, p53, and p21waf.
(B) Immunoblots of lysates prepared from IMR-32 cells grown for
15 hrs after 254 nm UV-C irradiation (20 or 100 Joules/m2) probed
with antibodies to p73a and p53.
al., 1995; Versteeg et al., 1995). The disruption of p73,
Figure 5. Expression of Exogenous p73 and p53 in SK-N-AS cells
then, may be one in a number of events that contribute
(A) SK-N-AS cells were transfected with vectors expressing Neor
to the onset and progression of neuroblastoma.alone or together with p73a, the p73a mutant (R292H), p53, or
While the majority of neuroblastoma cell lines ana-p53(V143A), grown for 48 hr, and analyzed by Western blot using
lyzed here lacked p73 expression, we were able to de-antibodies to p53, p73, p21waf, and Bcl-2.
(B) Colony formation in SK-N-AS cells transfected as in (A) after tect protein in two exceptions: the SK-N-SH cell line,
growth for 3 weeks under G418 selection. which lacks detectable 1p or p73 LOH, and IMR-32,
which harbors a large 1p35-36 deletion characteristic
of N-myc-amplified neuroblastomas. Notably, sequence
analysis of p73 transcripts in both SK-N-SH and IMR-contrast, the more aggressive stage 3 and 4 neuro-
blastomas appear to have amplified N-Myc and have 32 revealed a dinucleotide A/T polymorphism in the 59
untranslated region. Using this polymorphism, we dem-sustained larger telomeric deletions, including 1p36 and
1p35 from chromosome 1 of random parental origin onstrated monoallelic expression of the p73 gene not
only in cell lines but also in peripheral blood cells of(Cheng et al., 1995). Whether 1p35 harbors additional
tumor suppressor genes or one that affects N-Myc am- normal donors. To date, we have analyzed only one
informative family regarding the parental dominance inplification or modifies expression of other genes on 1p
is unknown, but it is obvious that neuroblastoma is a expression of p73 alleles. In this case, a normal A/T;G/C
heterozygote donor was found to express the A/T allelehighly complex and heterogeneous disease involving
the disruption of activities at multiple loci. at the transcript level, while the maternal and paternal
genotypes were A/T;A/T and G/C;G/C, respectivelyThe chromosomal localization and monoallelic ex-
pression of p73, its frequent LOH in neuroblastoma, (data not shown). While obviously limited, this analysis
shows a case in which the p73 gene, like the putativeand its conspicuous lack of expression in a majority of
neuroblastoma cell lines are all consistent with the no- tumor suppressor at 1p36, is expressed predominantly
from the maternal allele. Further, is there any signifi-tion that p73 is a candidate for the putative, imprinted
neuroblastoma suppressor gene at 1p36. Importantly, cance to the observation that in the only two neuro-
blastoma lines examined with p73 protein expression,p73 maps to the distal border of the consensus deletion
found in neuroblastoma, as defined by a wide range of namely IMR-32 and SK-N-SH, this protein was derived
from an A/T transcript? At present, we have no experi-tumor cell lines (Cheng et al., 1996). It is interesting to
note, however, that a constitutional 1p36 deletion in one mental evidence for a functional difference between the
G/C and A/T alleles. We note, however, that the p73case reportedly retained the D1Z2 marker at 1p36.33
(Biegel et al., 1993). This potentially places p73 immedi- transcripts contain an in-frame CUG codon 59 of this
polymorphic region, which, at least in several genes,ately distal to the region of overlap between theconstitu-
tional case and deletions in neuroblastoma tumor cell including basic fibroblast growth factor and C-Myc, acts
as an alternative translation initiation codon (Prats etlines. It remains possible, nonetheless, that theconstitu-
tional deletion encompasses a region extremely close al., 1989). Moreover, conceptual translation from this
CUG codon yields a coding sequence somewhat homol-to p73 and could mediate its disruption without a strict
deletion of the gene. On the other hand, various studies ogous to that of the transcriptional activation domain
of p53. We are presently investigating the possibilityhave reported tumor cell lines and constitutional translo-
cations at 1p36 whose break points do not map within that this 59 CUG codon is in fact an alternative site for
the initiation of p73 translation.the deletion in SK-N-AS. This has led to the speculation
that multiple neuroblastoma suppressor genes exist at In this study, we concentrated on neuroblastoma cell
lines showing 1p LOH and found that the remaining p731p36 (Takeda et al., 1994; Amler et al., 1995; Laureys et
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allele lacked mutations similar to those that inactivate activities of p53 in cell growth regulation or promote
survival of a disregulated cell. Importantly, recent stud-p53. However, as only z30% to 40% of sporadic neuro-
blastoma tumors display an obvious 1p LOH (Caron et ies have begun to establish links between active cell cy-
cle progression and differentiation (Huttner and Brand,al., 1995), an extensive analysis of neuroblastoma tu-
mors will be required to determine the actual signifi- 1997), thereby suggesting a potential mechanism by
which p73 might be required for differentiation of neu-cance of p73 lesions, monoallelic expression, and the
A/T polymorphism in the development of neuroblastoma roectodermal stem cells. Analysis of p73 activity during
differentiation and throughout the cell cycle should pro-and other diseases.
vide insight into these issues.
It is unclear at present how the identification of thisp73 Function
The identification of p73, its homology with p53, and its novel gene will impact on our understanding of p53.
From an evolutionary standpoint, however, it is interest-link to tumor suppressors at 1p36 raise fundamental
questions regarding p73 function in development and ing to note that p73 shares greater homology with p53-
like proteins found in mollusks than with p53 itself. It iscell cycle control. Does p73, for instance, act in a manner
similar to p53 to sense cellular stresses such as DNA formally possible that p53 evolved from a more primitive,
p73-like gene involved in many aspects of differentiationdamage and hypoxia and integrate this information for
cell cycle and cell death regulation? Whereas p73 is and growth control to assume more specific functions
in cell cycle control and tumor suppression. It is alsoshown to be capable of enhancing levels of endogenous
p21waf protein, it is not induced in cell lines by agents, possible, given the general quadruplication of the Hox
complex and other essential genes at the chordate±including UV radiation and actinomycin D, that result in
p53 stabilization and activation. Although experiments vertebrate transition (Holland, 1996), that other p53-like
genes exist and comprise a p53 regulatory network.are under way to determine what signals influence p73
expression, it is apparent that p73 and p53 may be Finally, the discovery of a gene related to p53 will
likely contribute to our understanding of the complexserving distinct functions in the cell. An equally pressing
question is whether p73 and p53 interact to yield novel etiology of neuroblastoma and other diseases involving
1p LOH and may lead to new avenues in developmentalactivities not displayed by either molecule alone. Given
the dramatic consequences of heterodimerization by and cell cycle regulation, tumor biology, and alternate
strategies for cancer therapy.members of the c-Myc family (c-Myc, Myb, Max, and
Mxi1) on target gene expression (Bernards, 1995), it will
be important to determine if such interactions occur Experimental Procedures
amongst p53-like proteins. Our initial efforts focused on
Tissue Culturethe yeast two-hybrid system for testing potential inter-
All cell lines were grown in Dulbecco's modified Eagle's mediumactions between p53 and p73. Interestingly, both p53
(DMEM) containing 4 g/l glucose, 10% fetal calf serum, 2 mM gluta-and p73b show strong homotypic interactions, while
mine, and 5000 mg/ml penicillin and streptomycin.
p73a has a very low propensity for self interactions in
this assay. Moreover, p73b displays an ability to interact
Two-Hybrid Assay
with both p73a and p53, despite its preferential associa- The two-hybrid assay was performed essentially as described (Gy-
tion with other p73b molecules. Although we are pres- uris et al., 1993). Nucleotide sequences corresponding to amino
ently examining p73±p53 interactions in a variety of cells, acids 72±393 of p53, 85±636 of p73a, and 85±499 of p73b were
introduced into the vectors pEG202 (resulting in a fusion proteinthe data obtained from the yeast interaction assay sug-
with the LexA DNA-binding domain) and pJG4-5 (resulting in a fusiongest that such interactions are possible and may be
protein with a transcriptional activation domain). The yeast strainlikely. The analysis of p73±p53 interactions in cells may
EGY48 was transformed with a pEG202 plasmid, a pJG4-5 plasmid,
be especially critical for understanding neuroblastoma, and the pSH18.34 plasmid containing the lacZ gene under the con-
as p53 is often wild type in this disease, and yet recent trol of eight lexA operators.
studies indicate that it is aberrantly cytoplasmic (Moll
et al., 1995). An intriguing, though speculative, explana- p21waf Protein Induction Assay
tion for this unusual behavior of p53 in neuroblastoma p73 cDNAs were cloned into a pCMV1 vector containing a 200 bp
lamin 59-untranslated region and encoding an N-terminal myc tagis that p53 requires p73 for some activities that are lost
(Heald et al., 1993). pCMV-p53 and pCMV-p53V143A were gifts ofin the absence of p73. Definitive answers to whether p73
Dr. Bert Vogelstein (Baker et al., 1990). IMR-32 cellswere transfectedhas consequential interactions with p53 will obviously
on 100 mm plates with 20 mg of the indicated plasmid and extractsrequire extensive genetic and biochemical studies.
prepared by lysis in SDS sample buffer. Lysates were fractionated
Major questions remain for understanding possible on a 10% polyacrylamide gel and transferred to Immobilon mem-
p73 functions in cell cycle regulation and growth control. branes by electrophoresis. Membranes were probed with a p21
Curiously, the majority of nonneuroblastoma tumor cell polyclonal antibody (Calbiochem) and developed by chemilumines-
cence (Pierce).lines was found to express high levels of wild-type p73
transcript and protein, suggesting a role for p73 in prolif-
DNA Damage Responseeration. This observation is perplexing in that most nor-
Cell lines, including IMR-32, MCF-7, and SK-N-SH, were grown tomal tissues show low levels of p73 transcript and protein
50% confluence and incubated with either 1 nM or 1 mM actinomycin(data not shown). One possible explanation for elevated
D (Calbiochem) for 24 hrs and 2 hrs, respectively. Cells were then
p73 in tumor cell lines is that a disruption of normal p53 washed with PBS, lysed in 23 SDS sample buffer, fractionated
function, as seen in a majority of these cell lines, results on 10% polyacrylamide gels, and electrophoretically transferred to
in compensatory or deleterious upregulation of p73 ex- Immobilon (Millipore) membranes. Membranes were probed with a
polyclonal antibody to p73a, a monoclonal antibody to p53 (ATCC,pression. In this scenario, p73 may then either assume
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Bethesda), or a monoclonal antibody to p21 (Calbiochem). For ex- 59CACCTGCTCCAGGGATGC and 59AAAATAGAAGCGTCAGTC de-
rived from intronic sequences were employed. For PCR-2, 2 ml ofamining responses to ultraviolet radiation, media was removed from
plates and cells exposed to 20 and 100 Joules/m2 254 nm UV-C. purified PCR-1 reaction products were used with a more internal
set of primers (59CAGGCCCACTTGCCTGCC and 59CTGTCCCCAAGMedia was returned to the plates and cells grown for an additional
15 hrs prior to lysis and Western blotting, as above. CTGATGA). The resulting amplicons were Sty1 digested and ana-
lysed on 1.5% agarose gels.
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